Clinical trial
An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients With Unresectable/Metastatic Melanoma.
NCT03269565 is registered in ClinicalTrials.gov with Biocad as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An International Multicenter Open-label Randomized Trial of the Efficacy, Pharmacokinetics, Safety, and Immunogenicity of BCD-100 (JSC BIOCAD, Russia) as Monotherapy in Patients With Unresectable/Metastatic Melanoma.
- Lead sponsor
- Biocad
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- August 31, 2017
- Completion date
- January 31, 2021
- Enrollment
- 126 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.